Laura A. Koutsky

Q: What Schools Are Affiliated With Laura A. Koutsky

Laura A. Koutsky is affiliated with the following schools: University of Melbourne, University of New Mexico, University of Washington

Laura A. Koutsky's AcademicInfluence.com Rankings

Laura A. Koutsky

Medical

#2890

World Rank

#3334

Historical Rank

Public Health

#455

World Rank

#470

Historical Rank

Epidemiology

#554

World Rank

#578

Historical Rank

medical Degrees

Laura A. Koutsky

Philosophy

#8279

World Rank

#11626

Historical Rank

Logic

#5314

World Rank

#6704

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Laura A. Koutsky's Degrees

Doctorate Medicine University of Washington
Masters Public Health University of Washington

Why Is Laura A. Koutsky Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Laura A. Koutsky's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. (2007) (1880)
A controlled trial of a human papillomavirus type 16 vaccine. (2002) (1763)
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions (2007) (1755)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. (2005) (1693)
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. (2003) (1071)
The epidemiology of human papillomavirus infections. (2005) (1029)
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection (1992) (978)
Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women (2006) (730)
Epidemiology of genital human papillomavirus infection. (1988) (722)
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. (2000) (576)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials (2007) (563)
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. (2010) (533)
Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. (1996) (530)
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. (2009) (509)
Factors That Are Associated With Parental Acceptance of Human Papillomavirus Vaccines: A Randomized Intervention Study of Written Information About HPV (2006) (505)
Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial (2006) (504)
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. (2006) (486)
Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. (2002) (484)
Epidemiology of genital human papillomavirus infection. (1997) (467)
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. (2009) (451)
Development and duration of human papillomavirus lesions, after initial infection. (2005) (423)
Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. (2000) (415)
Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis (2002) (389)
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. (1996) (348)
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial (2010) (341)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions (2009) (321)
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. (1998) (313)
Genital human papillomavirus infection in men. (2006) (276)
p16INK4a Expression Correlates with Degree of Cervical Neoplasia: A Comparison with Ki-67 Expression and Detection of High-Risk HPV Types (2003) (275)
Prematurity and perinatal mortality in pregnancies complicated by maternal Chlamydia trachomatis infections. (1982) (267)
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. (2004) (265)
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine (2002) (263)
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. (2002) (263)
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. (2007) (257)
Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. (2001) (253)
Risk of female human papillomavirus acquisition associated with first male sex partner. (2008) (245)
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. (1997) (242)
Vulvovaginal Candidiasis: Clinical Manifestations, Risk Factors, Management Algorithm (1998) (242)
Clinical manifestations of vaginal trichomoniasis. (1989) (233)
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. (2009) (223)
HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING, (2009) (220)
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection (2009) (215)
Concurrent and sequential acquisition of different genital human papillomavirus types. (2000) (196)
Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. (1995) (191)
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. (2008) (190)
Evidence of prevalent genital-type human papillomavirus infections in adults and children. (1990) (187)
A Case-Control Study of Necrotizing Fasciitis During Primary Varicella (1999) (183)
Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures (1992) (182)
Genital human papillomavirus infection in women who have sex with women. (1998) (164)
Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. (2000) (163)
Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. (1998) (160)
Risk for High-Grade Cervical Intraepithelial Neoplasia Associated with Variants of Human Papillomavirus Types 16 and 18 (2007) (156)
The Frequency of Unrecognized Type 2 Herpes Simplex Virus Infection Among Women Implications for the Control of Genital Herpes (1990) (153)
Circumcision and sexually transmitted diseases. (1994) (153)
Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications for Developing a Vaccination Strategy (2006) (153)
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. (2006) (152)
Puerperal infectious morbidity: relationship to route of delivery and to antepartum Chlamydia trachomatis infection. (1980) (148)
Chapter 13: Current findings from prophylactic HPV vaccine trials. (2006) (145)
Chlamydia trachomatis urethral infections in men. Prevalence, risk factors, and clinical manifestations. (1984) (143)
Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. (1989) (139)
Association Between Vaginal Douching and Acute Pelvic Inflammatory Disease (1990) (137)
Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women (2011) (133)
Natural history and epidemiological features of genital HPV infection. (1992) (131)
Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences (1985) (129)
Men's Perceptions and Knowledge of Human Papillomavirus (HPV) Infection and Cervical Cancer (2005) (117)
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. (2004) (113)
Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. (1995) (110)
Rates and Determinants of Oral Human Papillomavirus Infection in Young Men (2012) (110)
Determinants of cervical cancer rates in developing countries (2002) (103)
Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance (2011) (101)
Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. (2002) (100)
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. (2009) (97)
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. (2004) (96)
Relationship Between Cigarette Smoking and Human Papilloma Virus Types 16 and 18 DNA Load (2009) (96)
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. (1992) (95)
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. (1998) (95)
Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. (1995) (94)
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. (2008) (93)
Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. (1980) (93)
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia (2011) (92)
Genital human papillomavirus infection in women who have sex with women: a review. (2000) (92)
Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. (2004) (88)
Clinical findings among young women with genital human papillomavirus infection. (2003) (88)
Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women (2010) (87)
Association between vaginal douching and acute pelvic inflammatory disease. (1990) (87)
Genital Herpes in a Primary Care Clinic: Demographic and Sexual Correlates of Herpes Simplex Type 2 Infections (1997) (87)
High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. (2014) (76)
Longitudinal studies on chlamydial infections in the first year of life (1982) (74)
Identification of Human Papillomavirus Type 16 L1 Surface Loops Required for Neutralization by Human Sera (2006) (74)
Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. (1995) (73)
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. (2011) (70)
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. (2005) (68)
Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. (2000) (66)
Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour. (2001) (65)
Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. (2011) (65)
Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. (2008) (65)
Human Papillomavirus Infection and Cervical Cytology in Women Screened for Cervical Cancer in the United States, 2003–2005 (2008) (64)
Current findings from prophylactic HPV vaccine trials (2006) (63)
HLA class II DR-DQ and increased risk of cervical cancer among Senegalese women. (2001) (63)
Clinical presentation of genital warts among circumcised and uncircumcised heterosexual men attending an urban STD clinic. (1993) (61)
Obtaining Sensitive Data Through the Web: An Example of Design and Methods (2002) (60)
Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. (1993) (59)
Accuracy and Cost-Effectiveness of Cervical Cancer Screening by High-Risk Human Papillomavirus DNA Testing of Self-Collected Vaginal Samples (2010) (55)
Persistence of Mycoplasma hominis after therapy: importance of tetracycline resistance and of coexisting vaginal flora. (1983) (55)
Development of genital warts after incident detection of human papillomavirus infection in young men. (2010) (55)
HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS : SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING , NOVEMBER (2009) (55)
The Effect of Vaginal Speculum Lubrication on the Rate of Unsatisfactory Cervical Cytology Diagnosis (2002) (53)
Risk factors for HIV-1 shedding in semen. (1999) (51)
Prevalence and Cytologic Manifestations of Human Papilloma Virus (HPV) Types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, and 56 Among 500 Consecutive Women (1992) (47)
Detection of Genital HPV Types in Fingertip Samples from Newly Sexually Active Female University Students (2010) (47)
Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines (2007) (46)
Concordance of Self-Collected and Clinician-Collected Swab Samples for Detecting Human Papillomavirus DNA in Women 18 to 32 Years of Age (2006) (46)
Colposcopic manifestations of cervical and vaginal infections. (1988) (45)
Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya (2007) (43)
Characterization of IgA response among women with incident HPV 16 infection. (2003) (42)
Clinical features of Chlamydia trachomatis rectal infection by serovar among homosexually active men. (1999) (42)
Cigarette Smoking and Mortality Among HIV-Infected Individuals in Seattle, Washington (1996–2008) (2010) (40)
Genital papillomavirus infections: current knowledge and future prospects. (1989) (38)
Development and Evaluation of a Liquid Bead Microarray Assay for Genotyping Genital Human Papillomaviruses (2009) (38)
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine (2011) (37)
A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. (1999) (37)
Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. (1994) (37)
Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for cervical intraepithelial neoplasia. (2014) (37)
Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral (2010) (37)
Viral load and short‐term natural history of type‐specific oncogenic human papillomavirus infections in a high‐risk cohort of midadult women (2014) (36)
The epidemiology behind the HPV vaccine discovery. (2009) (35)
Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 Capsomers (2005) (35)
Characterization of three novel human papillomavirus types isolated from oral rinse samples of healthy individuals. (2014) (35)
Comparison of Southern transfer hybridization and dot filter hybridization for detection of cervical human papillomavirus infection with types 6, 11, 16, 18, 31, 33, and 35. (1990) (35)
Smokers at Higher Risk for Undetected Antibody for Oncogenic Human Papillomavirus Type 16 Infection (2006) (35)
Effect of Sexual Debut on Vaginal Microbiota in a Cohort of Young Women (2012) (34)
HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. (1993) (34)
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. (2012) (34)
Incident Detection of High-Risk Human Papillomavirus Infections in a Cohort of High-Risk Women Aged 25-65 Years. (2016) (33)
Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. (2009) (32)
Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. (2009) (32)
Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. (2009) (32)
Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. (2009) (31)
Type‐dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18 (2017) (31)
Using risk factors to predict human papillomavirus infection: implications for targeted vaccination strategies in young adult women. (2008) (30)
Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. (1999) (30)
Underestimation of HSV‐2 Seroprevalence in a High‐risk Population by Microneutralization Assay (1993) (30)
Prevalence and Risk Factors for Oncogenic Human Papillomavirus Infections in High-Risk Mid-Adult Women (2012) (30)
Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. (2008) (29)
The Inflammatory Papanicolaou Smear: What Does It Mean? (1995) (29)
Age of Diagnosis of Squamous Cell Cervical Carcinoma and Early Sexual Experience (2009) (28)
Psychiatric comorbidity and length of stay in hospitalized AIDS patients. (1994) (27)
Re‐detection vs. new acquisition of high‐risk human papillomavirus in mid‐adult women (2016) (24)
Re: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. (2004) (24)
Liquid‐based Papanicolaou Smears Without a Transformation Zone Component: Should Clinicians Worry? (2002) (24)
Human papillomavirus through the ages. (2005) (23)
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. (2007) (23)
Rapid and inexpensive approaches to managing abnormal vaginal discharge or lower abdominal pain: an evaluation in women attending gynaecology and family planning clinics in Peru. (1998) (23)
Evaluation of Transported Dry and Wet Cervical Exfoliated Samples for Detection of Human Papillomavirus Infection (2010) (23)
Potential Impact of Human Papillomavirus Vaccines on Public STD Clinic Workloads and on Opportunities to Diagnose and Treat Other Sexually Transmitted Diseases (2007) (22)
Behavior in Early Adolescence and Risk of Human Papillomavirus Infection as a Young Adult: Results From a Population-Based Study (2008) (22)
Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. (2009) (22)
Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing. (2012) (21)
Do our current cervical cancer control strategies still make sense? (1996) (20)
Circumcision and Acquisition of Human Papillomavirus Infection in Young Men (2011) (20)
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development (2009) (20)
Inverse Association between Methylation of Human Papillomavirus Type 16 DNA and Risk of Cervical Intraepithelial Neoplasia Grades 2 or 3 (2011) (20)
Evaluation of an ELISA for p16INK4a as a Screening Test for Cervical Cancer (2009) (20)
Use of hospital services by AIDS patients with psychiatric illness. (1998) (20)
Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. (2007) (19)
Epidemiology of Human Papillomavirus Detected in the Oral Cavity and Fingernails of Mid-Adult Women (2015) (19)
Obtaining sensitive data through the Web (2002) (18)
Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. (2008) (18)
The association of current hormonal contraceptive use with type-specific HPV detection (2011) (17)
National burden of genital warts: a first step in defining the problem. (2008) (16)
Delivering reassurance to parents: perinatal human papillomavirus transmission is rare. (2004) (16)
Short‐term natural history of high‐risk human papillomavirus infection in mid‐adult women sampled monthly (2015) (15)
Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. (2006) (15)
Sequence Variation of Human Papillomavirus Type 16 and Measurement of Viral Integration by Quantitative PCR (2009) (15)
Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection (1981) (14)
Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. (2010) (13)
Genomic Variation of Human Papillomavirus Type 16 and Risk for High-Grade Cervical Intraepithelial Neoplasia (1998) (13)
Epidemiology of genital human papillomavirus infections (1997) (13)
Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. (2013) (13)
Prevalence of High-Risk HPV Types and Abnormal Cervical Cytology in American Indian/Alaska Native Women, 2003–2005 (2011) (12)
Comparison of Variant-Specific Hybridization and Single-Strand Conformational Polymorphism Methods for Detection of Mixed Human Papillomavirus Type 16 Variant Infections (1999) (11)
Role of epidemiology in defining events that influence transmission and natural history of anogenital papillomavirus infections. (1991) (10)
Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. (2009) (9)
Comment on: Human papillomavirus type 16 and 18 variants : Race-related distribution and persistence. Authors' reply (2007) (8)
Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. (2009) (8)
Should Liquid-Based Cytology Be Repeated at the Time of Colposcopy? (2005) (8)
Bacterial infections in adult patients hospitalized with AIDS: case-control study of prophylactic efficacy of trimethoprim-sulfamethoxazole versus aerosolized pentamidine (1997) (8)
Genital infectious agents and invasive cervical cancer (1993) (8)
Monitoring HPV type-specific prevalence over time through clinic-based surveillance: a perspective on vaccine effectiveness. (2012) (8)
Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour (2001) (6)
Detection of Human Papillomavirus Infections at the Single-Cell Level (2016) (6)
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 (2005) (5)
Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships (2014) (5)
Diagnostic accuracy of HIV-associated central nervous system toxoplasmosis (1998) (5)
Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women (2016) (5)
Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3 (2015) (5)
Disclosure of genital human papillomavirus infection to female sex partners by young men. (2012) (4)
Will new human papillomavirus diagnostics improve cervical cancer control efforts? (2001) (4)
Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3 (2019) (3)
Sexual Behavior Patterns and Condom Use in Newly Sexually Active Female University Students (2020) (3)
Would Young Women Attending Sexually Transmitted Disease Clinics Benefit From Human Papillomavirus Vaccination? An Assessment of Human Papillomavirus DNA and Seropositivity From Human Papillomavirus Sentinel Surveillance, 2003–2005 (2014) (3)
Multiple Conformational Epitopes Are Recognized by Natural and Induced Immunity to the E7 Protein of Human Papilloma Virus Type 16 in Man (2000) (2)
Incidence of oral human papillomavirus infection (2013) (2)
Prevention of HPV-related cancers through immunization. (2006) (2)
HLA Class II DR-DQ and Increased Risk of Cervical Cancer among Senegalese Women 1 (2001) (2)
Information About HPV Papillomavirus Vaccines : A Randomized Intervention Study of Written Factors That Are Associated With Parental Acceptance of Human (2006) (1)
Re: Emerging technologies and cervical cancer. (2000) (1)
A quadrivalent vaccine prevented persistent infection and disease associated with HPV types 6, 11, 16, and 18 (2005) (1)
TWO AUTHORS REPLY (2003) (1)
HPV-16 vaccine prevented persistent HPV-16 infection and the development of HPV-16 related cervical neoplasia (2003) (1)
Current Progress in Vaccines for Viral STDs (2005) (1)
Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing. (2013) (1)
Condom use and the risk of HPV infection [10] (2006) (0)
Targeting Populations Based on Available (Licensed) Vaccines and Results of Controlled Efficacy Trials (2007) (0)
Selected Abstracts (2001) (0)
Chlamydia trachomatis Urethral Infections in Men (2020) (0)
Sexual Behavior Patterns and Condom Use in Newly Sexually Active Female University Students (2019) (0)
Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type-Speciﬁc Infection during a 2-Year Follow-Up (2009) (0)
HPV Vaccines: Getting it to the Developing World (2008) (0)
SEXTRANS44354-1906 372..376 (2011) (0)
Drs. Garland and Koutsky reply [6] (2007) (0)
Human Papillomavinis Infection Increases Risk for Intraepithelial Neoplasla (1993) (0)
Ibuprofen as a risk factor for necrotizing fasciitis during primary varicella in children (1997) (0)
Douching practice in pregnancy and pregnancy outcomes (1997) (0)
Type 16 Variant Infections Detection of Mixed Human Papillomavirus Conformational Polymorphism Methods for Hybridization and Single-Strand Comparison of Variant-Specific (1999) (0)
The HPV Vaccine: Will it one day wipe out cervical Ca? (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Laura A. Koutsky?

Laura A. Koutsky is affiliated with the following schools:

Laura A. Koutsky's Academic­Influence.com Rankings

Laura A. Koutsky's Degrees

Why Is Laura A. Koutsky Influential?

Laura A. Koutsky's Published Works

Published Works

What Schools Are Affiliated With Laura A. Koutsky?

Laura A. Koutsky's AcademicInfluence.com Rankings